NEWS

Novel intrasaccular aneurysm treatment device receives FDA PMA approval

The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysmsAliso Viejo, CA. – January 7, 2019 – MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB System is the first and only PMA approved device in the new category of intrasaccular flow disruptors for aneurysm embolization. (The WEB System was developed by Sequent Medical, Inc. and Sequent was acquired by Terumo in 2016).

Feel the vibe of LINNC Asia seminar 2018!

DCB angioplasty for MCA stenosis

Foramen magnum dural AVF

Cerenovus launches largest global registry to study stroke-inducing bloo...

Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood ClotsIRVINE, Calif., Dec. 10, 2018 -- Johnson & Johnson Medical Devices Companies* today announced that its CERENOVUS business has launched the single largest global registry, the EXCELLENT Registry, to collect and analyze stroke-inducing blood clots removed from the brain with its EMBOTRAP II Revascularization Device, a next generation stent retriever used in mechanical thrombectomy.

Pediatric giant basilar top aneursym

3rd regional course in diag. and treatment of ICH

Don't miss the best of LINNC Asia 2018

AVM treated with PHIL

Chasing sunshine at LINNC Americas Miami 2019!